SCHEMBL1818243

SCHEMBL1818243

CC(CCc1ccccc1)(C(N)=O)c1ccccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN2A Q99250 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 2/20 0.38
P2RX7 Q99572 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
ADRA1A P35348 1/20 0.38
OPRK1 P41145 1/20 0.38
KCNH2 Q12809 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
KIF11 P52732 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1819683 0.84 GPR52 (0.41) POLBL3MBTL1SCN5ASCN2ANPC1
SCHEMBL4560574 0.80 MAPT (0.52) POLBL3MBTL1NPC1RAB9AMAPT
SCHEMBL1822592 0.78 NPSR1 (0.47) POLBL3MBTL1NPC1RAB9AMAPT
SCHEMBL6803588 0.76 HDAC3 (0.50) POLBL3MBTL1NPC1RAB9AMAPT
SCHEMBL17555371 0.74 KCNN4 (0.43) L3MBTL1MAPTHTR2AHTR2CADRA1A
SCHEMBL21632104 0.73 KCNN4 (0.42) L3MBTL1MAPTHTR2AHTR2CADRA1A
SCHEMBL9190217 0.73 GRM2 (0.46) POLBL3MBTL1NPC1RAB9AMAPT
SCHEMBL5320849 0.73 MAPT (0.46) POLBL3MBTL1NPC1RAB9AMAPT
SCHEMBL27957913 0.73 AR (0.47) POLBL3MBTL1NPC1RAB9AMAPT
SCHEMBL19815146 0.72 MAPT (0.53) POLBL3MBTL1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 POLB 1708/4885L3MBTL1 3669/4885SCN5A 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.